Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.17 USD | -4.56% | -3.88% | -20.76% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.76% | 246M | |
+12.15% | 228B | |
+14.90% | 196B | |
+18.22% | 141B | |
+29.15% | 110B | |
+0.53% | 65.88B | |
+16.92% | 54.3B | |
+6.33% | 52.39B | |
+10.93% | 45.22B | |
+5.87% | 37.12B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Morgan Stanley Adjusts NeuroPace Price Target to $9 From $8, Maintains Equal Weight Rating